Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 6/20 | 0.48 |
| ▸ | PRMT6 | Q96LA8 | 6/20 | 0.48 |
| ▸ | PRMT8 | Q9NR22 | 2/20 | 0.48 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.48 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 4/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 4/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26494036 | 1.00 | CARM1 (0.48) | CARM1PRMT6PRMT8PRMT1SPHK1 | |
| SCHEMBL26495258 | 0.98 | CARM1 (0.50) | CARM1PRMT6PRMT8PRMT1SPHK1 | |
| SCHEMBL14272558 | 0.92 | CARM1 (0.52) | CARM1PRMT6PRMT8PRMT1SPHK1 | |
| SCHEMBL1108189 | 0.84 | CARM1 (0.67) | CARM1PRMT6PRMT8PRMT1SIGMAR1 | |
| SCHEMBL23506931 | 0.83 | CARM1 (0.71) | CARM1PRMT6PRMT8PRMT1SIGMAR1 | |
| SCHEMBL12291008 | 0.81 | CARM1 (0.44) | CARM1PRMT6PRMT8PRMT1 | |
| SCHEMBL12291015 | 0.81 | CARM1 (0.44) | CARM1PRMT6PRMT8PRMT1 | |
| SCHEMBL13822620 | 0.80 | CARM1 (0.54) | CARM1PRMT6PRMT8PRMT1GNAI3 | |
| SCHEMBL1891298 | 0.79 | GNAO1 (0.63) | SPHK1GNAI3GNAO1GNAI1 | |
| SCHEMBL19603949 | 0.79 | GNAO1 (0.63) | SPHK1GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2023196444-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | PLTP, LNPEP, PLIN3 | CARM1 3427/4885PRMT6 3265/4885PRMT8 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.